The Latest Breaking News from LLY

Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs

Eli Lilly And Co (NYSE:LLY) has officially become the giant quietly moving the strings behind a large slice of the pharma ETF universe. With blockbuster revenue growth, repeated earnings beats and a pipeline that refuses to slow down, Lilly isn’t just lifting its own stock – it’s powering a growing…

Benzinga · Nov 15, 2025

Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since

Eli Lilly's blockbuster drug Zepbound could be getting a big new customer: Medicare. See the implications of the company's recent deal with President Trump.

MarketBeat · Nov 14, 2025

Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch

Eli Lilly Co. (NYSE:LLY) is reportedly dropping CVS Health Inc.'s (NYSE:CVS) drug benefit plan for its employees.

Benzinga · Nov 12, 2025

Eli Lilly Posts Stellar Q3: Long-Term Upside Is Well in Play

Eli Lilly just posted its fastest revenue growth ever, putting shares up 40% in less than three months. The stock continues to have strong long-term potential.

MarketBeat · Nov 4, 2025

Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House

Eli Lilly and Company (NYSE:LLY) shares are in the spotlight following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement options.

Benzinga · Nov 4, 2025

Are Wall Street Analysts Predicting Eli Lilly Stock Will Climb or Sink?

While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.

Barchart · Nov 4, 2025

What's Up With The Rise In Eli Lilly Stock Today?

Eli Lilly and Company (NYSE:LLY) shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion for oral medicine.

Benzinga · Nov 3, 2025

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.

Benzinga · Oct 31, 2025

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

Benzinga · Oct 30, 2025

Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday?

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome Powell the day before.

Benzinga · Oct 30, 2025